PROTHENA CORPORATION PUBLIC LIMITED COMPANY APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $5.58 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2020-11-04
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2020-09-30 was $5.58M, a 4.01% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2020-06-30 was $5.69M, a 9.40% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-09-30 was $5.82M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2019-06-30 was $6.28M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2020-09-30 | $5.58M 10-Q · filed 2020-11-04 | $11.27M derived: sum of 2 quarters · filed 2020-11-04 | $16.81M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.69M 10-Q · filed 2020-08-06 | $11.22M 10-Q · filed 2020-08-06 | |
| 2019-09-30 | $5.82M 10-Q · filed 2020-11-04 | $12.09M derived: sum of 2 quarters · filed 2020-11-04 | $18.30M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $6.28M 10-Q · filed 2020-08-06 | $12.48M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |